Table 2 Patients’ treatment and outcome
Patient | Primary diagnosis | Age at treatment | Treatment | CSI/SI Dose (Gy) | CSI/SI Dose per Fraction (Gy) | Boost Region | Cumulative dose in boosted volume (Gy) | Boost Dose per Fraction (Gy) | Reason for treatment discontinuation | Clinical treatment benefit | Prognostic Score | Survival (months) | Patient alive at last follow up |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NSCLC | 64 | CSI | 20,8 | 1.6 | no Boost | NA | NA | clinical progress, deterioration of physical condition | No | 2 | 1.5 | No |
2 | Breast cancer | 37 | CSI | 35.2 | 1.6 | Posterior fossa | 50.0 | 2.0 | NA | No | 1 | 3.8 | No |
3 | Breast cancer | 58 | CSI | 18.0 | 1.8 | A) Sacrl cauda equina B) whole brain - C7 | A)26.0 B) 37.0 | A) 2 × 2.0 B) 2 × 2.0 + 5 × 3.0 | Grade III Leuko- and Thrombopaenia | Improvement in paresis, headaches and dizziness | 0 | 4.7 | No |
4 | NSCLC | 70 | CSI | 36.0 | 1.8 | Sacrum | 43.5 | 2.5 | NA | Pain reduction | 1 | 3.3 | No |
5 | Breast cancer | 63 | CSI | 21.6 | 1.8 | Radiosurgery Boost to four brain metastases | 37.6 | 16.0 | Grade III Leuko- and Thrombopaenia | No | 1 | 3.3 | No |
6 | Primary CNS Lymphoma | 67 | SI | 21.0 | 1.5 | L3-S1, whole brain | 30.0 | 3.0 | Grade III Leuko- and Grade IV Thrombopaenia | No | 0 | 1.9 | No |
7 | DLBCL | 64 | SI | 3.0 | 1.5 | Th8 - Sacrum | 9.0 | 3.0 | Grade IV Leuko- and Grade III Thrombopaenia | No | 1 | 0.5 | No |
8 | NSCLC | 80 | CSI | 30.6 | 1.8 | Th11-S2 | 40.6 | 2.0 | clinical progress, deterioration of physical condition | No | 2 | 1.5 | No |
9 | NSCLC | 48 | CSI | 36.0 | 1.5 | no Boost | NA | NA | NA | Pain reduction | 0 | 61.5 | Yes |
10 | Anaplastic Astrocytoma | 63 | CSI | 36.0 | 1.8 | A) C2-C6,Th1-Th2, Th6-Th10 B) left cerebellum | A) 45.0 B) 54.0 | 1.8 | NA | Improvement of dizziness | 0 | 16.3 | Yes |
11 | Sarcomatoid CUP | 41 | CSI | 23.6 | 1.6 | no Boost | NA | NA | clinical progress, deterioration of physical condition | No | 1 | 1.6 | No |
12 | Adenocarcinoma of Gastroesophagheal Junction | 48 | CSI | 14.8 | 1.8 | C6, Th5–6, L1–5 | 24.8 | 2.0 | clinical progress, deterioration of physical condition, massive thrombosis | No | 2 | 0.9 | No |
13 | Gastric Cancer | 36 | CSI | 30.0 | 1.5 | Posterior fossa, TH7 | 36.0 | 1.8 | NA | Improvement of blurred vision and paraesthesia and ataxia | 0 | 3.4 | No |
14 | Embryonal Carcinoma (NOS) | 47 | SI | 32.0 | 1.6 | no Boost | NA | NA | NA | Improvement of Paresis | 2 | 2.8 | No |
15 | MPNST | 31 | CSI | 35.2 | 1.6 | Posterior fossa | 54.0 | 2.0 | NA | Improvement in general physical condition, better mobilisation, pain reduction | 1 | 8.4 | No |
16 | Mantel Cell Lymphoma | 70 | CSI | 28.8 | 1.8 | no Boost | NA | NA | Grade IV Leukopaenia | No but negativ spinal tap one month after CSI | 0 | 7.3 | No |
17 | NSCLC | 56 | SI | 36.0 | 1.8 | A) Th9–10 B) L3 -S2 | A) 44.0 B) 50.0 | A) 2.2 as simultaneuous integrated boost B) 2.2 as simultaneuous integrated boost followed by 2 × 3.0 | NA | Improvement of bladder incontinence and paresis | 1 | 4.2 | No |
18 | Breast Cancer | 69 | CSI | 36.0 | 1.8 | no Boost | NA | NA | NA | Almost complete regression of sensory and motor deficits in the lower left extremity as well as complete regresion of the impairment in urinary and defecation function | 0 | 11.3 | Yes |
19 | Breast Cancer | 36 | CSI | 35.2 | 1.6 | no Boost | NA | NA | NA | Improvement in general clinical condition, pain and sensitive neurological deficits | 0 | 13.0 | No |